The bioenergetics of cancer: Is glycolysis the main ATP supplier in all tumor cells?

BioFactors

Volumn 35, Issue 2, 2009, Pages 209-225

  Moreno Sánchez, Rafael ^a   Rodríguez Enríquez, Sara ^a   Saavedra, Emma ^a   Marín Hernández, Alvaro ^a   Gallardo Pérez, Juan Carlos ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Glycolysis; Metabolic control analysis; Mitochondrial function; Oxidative phosphorylation; PET

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 4 HYDROPEROXYCYCLOPHOSPHAMIDE; 6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; ARSENIC TRIOXIDE; CAMPTOTHECIN; CARBOXYATRACTYLOSIDE; CARMUSTINE; CISPLATIN; CITRININ; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUCYTOSINE ARABINOSIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GOSSYPOL; HEXOKINASE; IODOACETIC ACID; LACTATE DEHYDROGENASE; MELPHALAN; MITOCHONDRIAL DNA; OLIGOMYCIN; OXYGEN; PACLITAXEL; ROTENONE; VINBLASTINE; VINCRISTINE;

AEROBIC METABOLISM; BIOENERGY; CANCER CELL; CELL PROLIFERATION; CITRIC ACID CYCLE; ENERGY METABOLISM; GENETIC REGULATION; GLYCOLYSIS; HUMAN; HYPOXIA; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONCENTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL; TUMOR GROWTH; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MITOCHONDRIA; NEOPLASMS;

EID: 67649220648     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.31     Document Type: Review

References (149)

1. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314.
2. Moreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A., and Saavedra, E. (2007) Energy metabolism in tumor cells. FEBS J. 274, 1393-1418.
3. Reske, S. N., Grillenberger, K. G., Glatting, G., Port, M., Hildebrandt, M., Gansauge, F., and Beger, H. G. (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med. 38, 1344-1348.
4. Medina, R. A., and Owen, G. I. (2002) Glucose transporters: expression, regulation and cancer. Biol. Res. 35, 9-26.
5. Noguchi, Y., Marat, D., Saito, A., Yoshikawa, T., Doi, C., Fukuzawa, K., Tsubaraya, A., Satoh, S., and Ito, T. (1999) Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 46, 2683-2689.
6. Medina, R. A., Meneses, A. M., Vera, J. C., Guzmán, C., Nualart, F., Rodríguez, F.De los Angeles García, M., Kato, S., Espinoza, N., Monso, C., Carvajal, A., Pinto, M., and Owen, G. I. (2004) Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J. Endocrinol. 182, 467-478.
7. Ciampi, R., Vivaldi, A., Romeo, C., Del Guerra, A., Salvadori, P., Cosci, B., Pinchera, A., and Elisei, R. (2008) Expression analysis of facilitative glucose transporters (GLUTs) in human tyroid carcinoma call lines and primary tumors. Mol. Cell. Endocrinol. 291, 57-62.
8. Meneses, A. M., Medina, R. A., Kato, S., Pinto, M., Jaque, M. P., Lizama, I., de L. García, M., Nualart, F., and Owen, G. I. (2008) Regulation of GLUT3 and glucose uptake by the cAMP signaling pathway in the breast cancer cell line ZR-75. J. Cell Physiol. 214, 110-116.
9. Yeh, C. S., Wang, J. Y., Chung, F. Y., Lee, S. C., Huang, M. Y., Kuo, C. W., Yang, M. L., and Lin, S. R. (2008) Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. Oncol. Rep. 19, 81-91.
10. Marín-Hernández, A., Rodríguez-Enríquez, S., Vital-González, P. A., Flores-Rodríguez, F. L., Macias-Silva, M., Sosa-Garrocho, M., and Moreno-Sanchez, R. (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J. 273, 1975-1988.
11. Bennett, M. J., Timperley, W. R., Taylor, C. B., and Hill, A. S. (1978) Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur. J. Cancer 14, 189-193.
12. Paudyal, B., Oriuchi, N., Paudyal, P., Higuchi, T., Nakajima, T., and Endo, K. (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography. Cancer Sci. 99, 260-266.
13. Ong, L. C., Jin, Y., Song, I. C., Yu, S., Zhang, K., and Chow, P. K. (2008) 2-[(18)F]-2-Deoxy-D-Glucose (FDG) uptake in human tumor cells is related to the expresson of GLUT-1 and hexokinase II. Acta Radiol. 49, 1145-1153.
14. Vora, S., Halper, J. P., and Knowles, D. M. (1985) Alterations in the activity and isozymic profile of human phosphofructokinase durig malignant transformation in vivo and in vitro: Transformation-and progression-linked discriminants of malignancy. Cancer Res. 45, 2993-3001.
15. Ojika, T., Imaizumi, M., Abe, T., and Kato, K. (1991) Immunochemical and immunohistochemical studies on three aldolase isozymes in human lung cancer. Cancer 67, 2153-2158.
16. Takashima, M., Kuramitsu, Y., Yokoyama, Y., Iizuka, N., Fujimoto, M., Nishisaka, T., Okita, K., Oka, M., and Nakamura, K. (2005) Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteonomics 5, 1686-1692.
17. Chang, G. C., Liu, K. J., Hsieh, C. L., Hu, T. S., S.Charoenfuprasert, Liu, H. K., Luh, K. T., L.H.Hsu, C.W.Wu, Ting, C. C., Chen, C. Y., Chen, K. C., Yang, T. Y., Chou, T. Y., Wang, W. H., Whang-Peng, J., and Shih, N. Y. (2006) Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin. Cancer Res. 12, 5746-5754.
18. Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M., Mori, S., Oka, M., Hamano, K., Okita, K., Sakaida, I., and Nakamura, K. (2007) Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidence by proteonomic profiling by two-dimensional electrophoresis. Int. J. Oncol. 30, 849-855.
19. Simmonet, H., Alazard, N., Pfeiffer, K., Gallou, C., C.Béroud, Demont, J., Bouvier, R., Schagger, H., and Godinot, C. (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23, 759-768.
20. Wang, Y., Liu, V. W., Xue, W. C., Cheung, A. N., and Ngan, H. Y. (2006) Association of decreased mitochondrial DNA content with ovarian cancer progression. Br. J. Cancer 95, 1087-1091.
21. Funes, J., Quintero, M., Henderson, S., Martinez, D., Qureshi, U., Westwood, C., Clements, M. O., Bourboulia, D., Pedley, R. B., Moncada, S., and Boshoff, C. (2007) Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc. Natl. Acad. Sci. USA 104, 6223-6228.
22. Chatterjee, A., Mambo, E., and Sidransky, D. (2006) Mitochondrial DNA mutations in human cancer. Oncogene 25, 4663-4674.
23. Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7, 77-85.
24. Pollard, P. J., Briere, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., MacGrath, J. A., Gleeson, M. J., Hodgson, S. V., Puolsom, R., Rustin, P., and Tomlinson, I. P. (2005) Accumulation of Krebs cycle intermediates and overexpression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239.
25. Penta, J. S., Johnson, F. M., Wachsman, J. T., and Copeland, W.C. (2001) Mitochondrial DNA in human malignancy. Mutat. Res. 488, 119-133.
26. Stubbs, M., Bashford, C. L., and Griffiths, J. R. (2003) Understanding the tumor-metabolic phenotype in the genomic era. Curr. Mol. Med. 3, 49-59.
27. Balinsky, D., Platz, C. E., and Lewis, J. W. (1984) Enzyme activities in normal, dysplastic, and cancerous human breast tissues. J. Natl. Cancer. Inst. 72, 217-224.
28. Walenta, S., and Mueller-Klieser, W. F. (2004) Lactate: mirror and motor of tumor malignancy. Semin. Radiat. Oncol. 14, 267-274.
29. Altenberg, B., and Greulich, K. O. (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84, 1014-1020.
30. Robey, I. F., Lien, A. D., Welsh, S. J., Baggett, B. K., and Gillie, R. J. (2005) Hypoxia-inducible factor-1a and the glycolytic phenotype in tumors. Neoplasia 7, 324-330.
31. Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., and Plate, K. H. (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443.
32. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., and Denko, N. C. (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187-197.
33. Kim, J. W., Tchernyshyov, I., Semenza, G. L., and Dang, C. V. (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell. Metab,3, 177-185.
34. McFate, T., Mohyeldin, A., Lu, H., Thakar, J., J.Henriques, Halim, N. D., Wu, H., Schell, M. J., Tsang, T. M., Teahan, O., Zhou, S., Califano, J. A., Jeoung, N. H., Harris, R. A., and Verma, A. (2008) Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 283, 22700-22708.
35. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11, 37-51.
36. Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., and Dang, C. V. (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 29, 21797-21800.
37. Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L., and Dang, C. V. (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381-7391.
38. Rimpi, S., and Nilsson, J. A. (2007) Metabolic enzymes regulated by the Myc oncogene are possible targets for chemotherapy or chemoprevention. Biochem. Soc. Trans. 35, 305-310.
39. Li, F., Wang, Y., Keller, K. I., Potter, J. J., Wonsey, D. R., O'Donnell, K. A., Kim, J. W., Yustein, J. T., Lee, L. A., and Dang, C. V. (2005) Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225-6234.
40. Arango, D., Mariadson, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., Aranes, M. J., and Augenlicht, L. H. (2003) c-Myc overexpression sensitizes colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer 89, 1757-1765.
41. Jensen, N. A., Pedersen, K. M., Lihme, F., Rask, L., Nielsen, J. V., Rasmussen, T. E., and Mitchelmore, C. (2003) Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J. Biol. Chem. 278, 8300-8308.
42. Nesbit, C. E., Tersak, J. M., and Prochownik, E. V. (1999) MYC oncogenes and human neoplastic diseases. Oncogene 18, 3004-3016.
43. Robey, I. F., Stephen, R. M., Brown, K. S., Baggett, B. K., Gatenby, R. A., and Gillies, R. J. (2008) Regulation of the Warburg effect in earlypassage breast cancer cells. Mol. Cell. Biol. 27, 7381-7393.
44. Rapoport, T. A., Heinrich, R., and Rapoport, S. M. (1976) The regulatory principles of glycolysis in erythrocytes in vivo and in vitro. A minimal comprehensive model describing steady states, quasi-steady states and time-dependent processes. Biochem. J. 154, 449-469.
45. Torres, N. V., Mateo, F., Meléndez-Hevia, E., and Kacser, H. (1986) Kinetics of metabolic pathways. Biochem. J. 234, 169-174.
46. Torres, N. V., Souto, R., and Meléndez-Hevia, E. (1989) Study of flux and transition time control coefficient profiles in a metabolic system in vitro and the effect of an external stimulator. Biochem. J. 260, 763-769.
47. Kashiwaya, Y. K., Sato, K., Tsuchiya, N., Thomas, S., Fell, D. A., Veech, R. L., and Passonneau, J. V. (1994) Control of glucose utilization in working perfused rat heart. J. Biol. Chem. 269, 25502-25514.
48. Zamora-León, S. P., Golde, D. W., Concha, I. I., Rivas, C. I., Delgado-López, F., Baselga, J., Nualart, F., and Vera, J. C. (1996) Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA 93, 1847-1852.
49. Sakashita, M., Aoyama, N., Minami, R., Maekawa, S., Kuroda, K., Shirasaka, D., Ichihara, T., Kuroda, Y., Maeda, S., and Kasuga, M. (2001) Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur. J. Cancer 37, 204-209.
50. Rudlowski, C., Becker, A. J., Schroder, W., Rath, W., Buttner, R., and Moser, M. (2003) GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am. J. Clin. Pathol. 120, 691-698.
51. Pedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., and Ko, Y. H. (2002) Mitochondrial bound type II hexokinase. Biochim. Biophys. Acta 1555, 14-20.
52. Wilson, J. E. (2003) Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 206, 2049-2057.
53. Geschwind, J. F., Ko, Y. H., Torbenson, M. S., Magee, C., and Pedersen, P. L. (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 62, 3909-3913.
54. Xu, R., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., Bhalla, K. N., Keating, M. J., and Huang, P. (2005) Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613-621.
55. A.PPereira da Silva, El-Bacha, T., Kyaw, N., Sousa dos Santos, R., Seixas da-Silva, W., Almeida, F. C. L., Da Poian, A. T., and Galina, A. (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate1. Biochem. J. 417, 717-726.
56. Rodríguez-Enríquez, S., Marín-Hernández, A., Gallardo-Pérez, J. C., Carreño-Fuentes, L., and Moreno-Sánchez, R. (2009) Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 53, 29-48.
57. Sánchez-Martínez, C., and Aragón, J. J. (1997) Analysis of phosphofructokinase subunits and isozymes in ascites tumor cells and its original tissue, murine mammary gland. FEBS Lett. 133, 86-90.
58. Dunaway, G. A., Kasten, T. P., Sebo, T., and Trapp, R. (1988) Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem. J. 251, 677-683.
59. Sánchez-Martínez, C., Estévez, A. M., and Aragón, J. J. (2000) Phosphofructokinase c isozyme from ascites tumor cells: cloning, expression, and properties. Biochem. Biophys. Res. Commun. 271, 635-640.
60. Oskam, R., Rijksen, G., Staal, G. E. J., and Vora, S. (1985) Isozymic composition and regulatory properties of phosphofructokinase from well-differentiated and anaplastic medullary thyroid carcinomas of the rat. Cancer Res. 45, 135-142.
61. Staal, G. E. J., Kalff, A., Heesbeen, E. C., van Veelen, C. W. M., and Rijksen, G. (1987) Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas. Cancer Res. 47, 5047-5051.
62. Koukourakis, M. I., Giatromanolaki, A., Simopoulos, C., Polychronidis, A., and Sivridis, E. E. (2005) Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis. Clin. Exp. Metastasis. 22, 25-30.
63. Fantin, V. R., St-Pierre, J., and Leder, P. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 9, 425-434.
64. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., Dalla-Favera, R., and Dang, C. V. (1997) c-Myc transactivation of LDHA: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94, 6658-6663.
65. Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O., and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942.
66. Pedersen, P. L. (1978) Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res. 22, 190-274.
67. Rodríguez-Enríquez, S., Kim, I., Currin, R. T., and Lemasters, J. J. (2006) Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. Autophagy 2, 39-46.
68. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., and Semenza, D. L. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of c-Myc activity. Cancer Cell. 11, 407-420.
69. Yu, M., Zhou, Y., Shi, Y., Ning, L., Yang, Y., Wei, X., Zhang, N., Hao, X., and Niu, R. (2007) Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life 59, 450-457.
70. Grogg, K. L., Padmalatha, C., and Leslie, K. O. (2002) Bronchial carcinoid tumor with crystalloid cytoplasmic inclusions. Arch. Pathol. Lab. Med. 126, 93-96.
71. Morton, R., Cunningham, C., Jester, R., Waite, M., Miller, N., and Morris, H. P. (1976) Alteration of mitochondrial function and lipid composition in Morris 7777 hepatoma. Cancer Res. 36, 3246-3254.
72. Besaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., Gottlieb, E., and Vousden, K. H. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 8180-8187.
73. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., and Hwang, P. M. (2006) p53 regulates mitochondrial respiration. Science 312, 1650-1653.
74. Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., and Beach, D. (2005) Glycolytic enzymes can modulate life span. Cancer Res. 65, 177-185.
75. Bourdon, J. C. (2007) p53 and its isoforms in cancer. Br. J. Cancer 97, 277-282.
76. Kroemer, G., and Pouyssegur, J. (2008) Tumor cell metabolism: Cancer's Achilles'Heel. Cancer Cell. 13, 472-482.
77. Brandon, M., Baldi, P., and Wallace, D. C. (2006) Mitochondrial mutations in cancer. Oncogene 25, 4647-4662.
78. Gottlieb, E., and Tomlinson, I.P. M. (2005) Mitochondrial tumour suppresors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857-866.
79. Franklin, R. B., and Costello, L. C. (2007) Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch. Biochem. Biophys. 463, 211-217.
80. Matheson, B. K., Adams, J. L., Zou, J., Patel, R., and Franklin, R. B. (2007) Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells. Prostate 67, 1211-1218.
81. Denko, N. C. (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705-713.
82. Reitzer, L. J., Wice, B. M., and Kennell, D. (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669-2676.
83. Rodríguez-Enríquez, S., Vital-González, P. A., Flores-Rodríguez, F. L., Marín-Hernández, A., Ruiz-Azuara, L., and Moreno-Sánchez, R. (2006) Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol. Appl. Pharmacol. 215, 208-217.
84. Guppy, M., Leedman, P., Zu, X., and Russell, V. (2002) Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem. J. 364, 309-315.
85. Singh, K. K., Desouki, M. M., Franklin, R. B., and Costello, L. C. (2006) Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol. Cancer 5, 14.
86. Srisawang, P., Chatsudthipong, A., and Chatsudthipong, V. (2007) Modulation of succinate transport in Hep G2 cell line by PKC. Biochim. Biophys. Acta 1768, 1378-1388.
87. Weerachayaphorn, J., and Pajor, A. M. (2008) Identification of transport pathways for citric acid cycle intermediates in the human colon carcinoma cell line, Caco-2. Biochim. Biophys. Acta 1778, 1051-1059.
88. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008).The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metabolism 7, 11-20.
89. Rofstad, E. R., and Halsor, E. F. (2000) Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60, 4932-4938.
90. Vaupel, P., and Mayer, A. (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239.
91. O2- and pH-gradients in multicellular spheroids and their relationship to cellular metabolism and radiation sensitivity of malignant human tumor cells. Biochim. Biophys. Acta 1227, 105-112.
92. Hunjan, S., Mason, R. P., Constantinescu, A., Peschke, P., Hahn, E. W., and Antich, P. P. (1998) Regional tumor oximetry: 19F NMR spectroscopy of hexafluorobenzene. Int. J. Radiat. Oncol. Biol. Phys. 41, 161-171.
93. Matsumoto, A., Sowers, A. L., Koscielniak, J. W., Trigg, N. J., Kuppusamy, P., Mitchell, J. B., Subramanian, S., Krishna, M. C., and Matsumoto, K. (2005) Absolute oxygen tension (pO(2)) in murine fatty and muscle tissue as determined by EPR. Magn. Reson. Med. 57, 1530-1535.
94. Evans, S. M., Du, K. L., Chalian, A. A., Mick, R., Zhang, P. J., Hahn, S. M., Quon, H., Lustig, R., Weinstein, G. S., and Koch, C. J. (2007) Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to pattern outcome. Int. J. Radiat. Oncol. Biol. Phys. 69, 1024-1031.
95. 2 tension measurements. Cancer Res. 51, 3316-3322.
96. Erickson, K., Braun, R. D., Yu, D., Lanzen, J., Wilson, D., Brizel, D. M., Secomb, T. W., Biaglow, J. E., and Dewhirst, M. W. (2003) Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation. Cancer Res. 63, 4705-4712.
97. Kolstad, P. (1968) Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand. J. Clin. Lab. Invest. Suppl. 196, 145-157.
98. Kallinowski, F., Schlenger, K. H., Runkel, S., Kloes, M., Stohrer, M., Okunieff, P., and Vaupel, P. (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 49, 3759-3764.
99. Mason, R. P., Rodbumrung, W., and Antich, P. P. (1996) Hexafluorobenzene: a sensitive 19F NMR indicator of tumor oxygenation. NMR Biomed. 9, 125-134.
100. Zhao, D., Constantinescu, A., Hahn, E. W., and Mason, R. P. (2001) Tumor oxygen dynamics with respect to growth and respiratory challenge: investigation of the Dunning prostate R3327-HI tumor. Radiat. Res. 156, 510-520.
101. Bratasz, A., Kulkarni, A. C., and Kuppusamy, P. (2007) A highly sensitive biocompatible spin probe for imaging of oxygen concentration in tissues. Biophys. J. 92, 2918-2925.
102. Froese, G. (1962) The respiration of ascites tumor cells at low oxygen concentrations. Biochim. Biophys. Acta 57, 509-519.
103. Gnaiger, E., Lassnig, B., Kuznetsov, A., Rieger, G., and Margreiter, R. (1998) Mitochondrial oxygen affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J. Exp. Biol. 201, 1129-1139.
104. Pecina, P., Gnaiger, E., Zeman, J., Pronicka, E., and Houštěk, T. (2004) Decreased affinity for oxygen of cytochrome-c oxidase in Leigh syndrome caused by SURF1 mutations. Am. J. Physiol. Cell. Physiol. 287, C1384-C1388
105. Mason, M. G., Nicholls, P., Wilson, M. T., and Cooper, C. E. (2006) Nitric oxide inhibition of respiration involves both competitive (heme) and noncompetitive (copper) binding to cytochrome c oxidase. Proc. Natl. Acad. Sci. USA. 103, 708-713.
106. Ebert, B. L., Gleade, J. M., O'Rourke, J. F., Bartlett, S. M., Poulton, J., and Ratcliffe, P. J. (1996) Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin. Biochem. J. 313, 809-814.
107. Kobayashi, S., and Milhorn, D. E. (2001) Hypoxia regulates glutamate metabolism and membrane transport in rat PC12 cells. J. Neurochem. 76, 1935-1948.
108. Muller, M., Siems, W., Buttgereit, F., Dumdey, R., and Rapoport, S. M. (1986) Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells. Eur. J. Biochem. 161, 701-705.
109. Zu, X. L., and Guppy, M. (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313, 459-465.
110. Nakashima, R. A., Paggi, M. G., and Pedersen, P. L. (1984) Contributions of glycolysis and oxidative phosphorylation to adenosine 50-triphosphate production in AS-30D hepatoma cells. Cancer Res. 44, 5702-5706.
111. Fell, D. (1997)Understanding the control of metabolism,Portland Press,London.
112. Moreno-Sánchez, R., Saavedra, E., Rodríguez- Enríquez, S., and Olín- Sandoval, V. (2008) Metabolic control analysis: A tool for designing strategies to manipulate metabolic pathways,J. Biomed. Biotechnol. 2008, Art. No.597913.
113. Rodríguez-Enríquez, S., Torres-Márquez, M. E., and Moreno-Sánchez, R. (2000) Substrate oxidation and ATP supply in AS-30D hepatoma cells. Arch. Biochem. Biophys. 375, 21-30.
114. Griguer, C. E., Oliva, C. R., and Gillespie, G. Y. (2005) Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J. Neurooncol. 74, 123-133.
115. Park, Y. W., Kim, S. H., and Kim, S. Z. (2007) A ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J. Cell Biochem. 102, 98-109.
116. Newell, K. J., and Tannock, I. F. (1989) Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res. 49, 4477-4482.
117. Weinhouse, S. (1956) On respiratory impairment in cancer cells. Science 124, 267-269.
118. Rodríguez-Enríquez, S., Gallardo-Pérez, J. C., Avilés-Salas, A., Marín- Hernández, A., Carreño-Fuentes, L., Maldonado-Lagunas, V., and Moreno- Sánchez, R. (2008) Energy metabolism transition in multi-cellular human tumor spheroids. J. Cell Physiol. 216, 189-197.
119. Murphy, B. J., Laderoute, V. R., Vreman, H. J., Grant, T. D., Gill, N. S., Stevenson, D. K., and Sutherland, R. M. (1993) Enhancement of heme oxygenase expression and activity in A431 squamous carcinoma multicellular tumor spheroids. Cancer Res. 53, 2700-2703.
120. Schmidt, H., Siems,W. G., Muller, M., Dumdey, R., and Rapoport, S. (1991) ATP-producing and consuming processes of Ehrlich mouse ascites tumor cells in proliferating and resting phases. Exp. Cell. Res. 194, 122-127.
121. Siems, W. G., Schmidt, H., Gruner, S., and Jakstadt, M. (2004) Balancing of energy-consuming processes of K 562 cells. Cell. Biochem. Funct. 10, 61-66.
122. Krieg, R. C., Knuechel, R., Schiffmann, E., Liotta, L. A., Petricoin, E. F., III, and Herrmann, P. C. (2004) Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 4, 2789-2795.
123. Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfor, K., Rofstad, E. K., and Mueller-Klieser, W. (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60, 916-921.
124. Macheda, M. L., Rogers, S., and Best, J. D. (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654-662.
125. Peng, S. Y., Lai, P. L., Pan, H. W., Hsiao, L. P., and Hsu, H. C. (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol. Rep. 19, 1045-1053.
126. Soderberg, K., Nissinen, E., Bakay, B., and Scheffler, I. E. (1980) The energy charge in wild-type and respiration-deficient Chinese hamster cell mutants. J. Cell Physiol. 103, 169-172.
127. Ohta, S. (2006) Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 25, 4768-4776.
128. Marks, D. C., Su, G. M., Davey, R. A., and Davey, M. W. (1996) Extended multidrug resistance in haemopoietic cells. Br. J. Haematol. 95, 587-595.
129. Harper, M. E., Antoniou, A., Villalobos-Manuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., Kupperman, J., Newell, E. W., Bespalov, I. A., Wallace, S. S., Liu, Y., J.Rogers, R., Gibbs, G. L., Leahy, J. L., Camley, R. E., Melamede, R., and Newell, M. K. (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 16, 1550-1557.
130. Koya, K., Li, Y., Wang, H., Ukai, T., Tatsuta, N., Kawakami, M., Shishido, T., and Chen, L. B. (1996) MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56, 538-543.
131. Dietzen, D. J., and Davis, E. J. (1994) Excess membrane cholesterol is not responsible for metabolic and bioenergetic changes in AS-30D hepatoma mitochondria. Arch. Biochem. Biophys. 309, 341-347.
132. Hu, Y., Moraes, C. T., Savaraj, N., Priebe, W., and Lampidis, T. J. (2000) Rho (0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin and other drugs. Biochem. Pharmacol. 60, 1897-1905.
133. Neuzil, J., Tomasetti, M., Mellick, A. S., Alleva, R., Salvatore, B. A., Birringer, B., and Fariss, M. W. (2004) Vitamin analogues: a new class of inducers of apoptosis with selective anti-cancer effect. Curr. Cancer Drug Targets 4, 267-284.
134. Smith, T. A. (2001) The rate-limiting step for tumor [18F] fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl. Med. Biol. 28, 1-4.
135. Czernin, J., and Phelps, M. E. (2002) Positron emission tomography scanning: current and future applications. Annu. Rev. Med. 53, 89-112.
136. Berberat, P., Friess, H., Kashiwagi, M., Beger, H. G., and B̈chler, M. W. (2004) Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr. Cancer Drug Targets 4, 355-372.
137. Chang, J. M., Lee, H. L., Goo, J. M., Lee, J. J., Chung, J. K., and Im, J. G. (2006) False positive and false negative FDG-PET scans in various thoracic diseases. Korean J. Radiol. 7, 57-69.
138. Kubota, R., Kubota, K., Yamada, S., Ido, T., and Tamashi, N. (1994) Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J. Nucl. Med. 35, 104-112. (Pubitemid 24018451)
139. Higashi, K., Ueda, Y., Seki, H., Yuasa, K., Oguchi, M., Noguchi, T., Taniguchi, M., Tonami, H., Okimura, T., and Yamamoto, I. (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J. Nucl. Med. 39, 1016-1020.
140. Han, H. S., Escalón, M. P., Hsiao, B., Sarefini, A., and Lossos, I. S. (2009) High incidence of false positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens. Ann. Oncol. 2, 309-318.
141. Endo, K., Oriuchi, N., Higuchi, T., Lida, Y., Hanaoka, H., Miyakubo, M., Ishikita, T., and Koyama, K. (2006) PET and PET/CT using 18FDG in the diagnosis and management of cancer patients. Int. J. Clin. Oncol. 11, 286-296.
142. Torizuka, T., Tamaki, N., and Inokuma, T. (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG/PET. J. Nucl. Med. 36, 1811-1817.
143. Haq, M. S., McCready, R. M., and Harmer, C. L. (2004) Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Nucl. Med. Commun. 25, 799-805.
144. Zimny, M., Gagel, B., Dimartino, E., Hamacker, K., Coenen, H. H., Westhofen, M., Eble, M., Buell, U., and Reinartz, P. (2006) FDG- a marker of tumour hypoxia? A comparison with [18F] fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging 33, 1426-1431.
145. Dietz, D. W., Dehdashti, F., Grigsby, P. W., Myalyapa, R. S., Myerson, R. J., Picus, J., Ritter, J., Lewis, J. S., Welch, M. J., and Siegel, B. A. (2008) Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis. Colon Rectum 51, 1641-1648.
146. Fujibayashi, Y., Taniuchi, H., Wada, K., Yonekura, Y., Konishi, J., Yokoyama, A. (1995) Differential mechanism of retention of Cu-pyruvaldehyde- bis(N4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging. Ann. Nucl. Med. 9, 1-5.
147. Jana, S., and Blaufox, M. D. (2006) Nuclear medicine studies of the prostate, testes, and bladder. Semin. Nucl. Med. 36, 51-72.
148. Liu, Y. (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9, 230-234.
149. Fisher, P. G., and Buffler, P. A. (2005) Malignant gliomas in 2005: where to go from here? JAMA 293, 615-617.